MAPT and Alzheimer disease: The revised criteria demand a significant episodic memory impairment which does not improve with cuing plus an abnormal result for at least one biomarker: mediotemporal atrophy on structural neuroimaging, an AD-typical pattern on functional neuroimaging (PET or SPECT), or AD-typical results for Abeta- and tau-protein in cerebrospinal fluid (CSF) analysis.